https://x.com/KobeissiLetter/status/2090048185859239959?s=20


https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/
이유: 최초로 개인 맞춤형 암 백신이 3상에서 유의미한 성과를 거둠